Clinical Trials Directory

Trials / Completed

CompletedNCT00897546

Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma

Multiplex Analysis of Serum Biomarkers for Prediction Interferon Therapy Response in Melanoma Patients

Status
Completed
Phase
Study type
Observational
Enrollment
1,716 (actual)
Sponsor
ECOG-ACRIN Cancer Research Group · Network
Sex
All
Age
18 Years – 120 Years
Healthy volunteers
Accepted

Summary

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help doctors learn how well patients will respond to treatment. PURPOSE: This laboratory study is looking at biomarkers to predict the response to interferon therapy in patients with melanoma.

Detailed description

OBJECTIVES: * Generate a comprehensive multiplexed array of melanoma-associated serological markers and validate it using serum samples from patients with melanoma and healthy control participants. * Determine changes in the profile of serological markers induced by interferon-alfa 2b (IFN-α2b) therapy. * Define panels of serological markers with prognostic and predictive power for IFN-α2b therapy responses in patients with melanoma. OUTLINE: This is a multicenter study. Serum samples are used for multiplex analyses. Biomarkers to be assessed include cytokines, chemokines, growth factors, angiogenic and antiangiogenic molecules, matrix metalloproteases (MMPs), tissue inhibitors of MMPs (TIMPs), melanoma-associated antigens, basic fibroblast growth factor, insulin-like growth factor I and II, thrombospondin, endostatin, angiostatin, vasostatin, and vascular endothelial growth factor inhibitor. PROJECTED ACCRUAL: A total of 1,716 samples will be accrued for this study.

Conditions

Interventions

TypeNameDescription
OTHERlaboratory biomarker analysis

Timeline

Start date
2007-06-01
Primary completion
2008-07-01
Completion
2008-07-01
First posted
2009-05-12
Last updated
2017-05-19

Source: ClinicalTrials.gov record NCT00897546. Inclusion in this directory is not an endorsement.